The small-molecule inhibitor of murine double minute (MDM-2), Nutlin-3, induced variable apoptosis in primary acute myeloid leukemia (AML) blasts and promoted myeloid maturation of surviving cells, as demonstrated by analysis of CD11b and CD14 surface antigens and by morphologic examination. Although the best-characterized activity of Nutlin-3 is activation of the p53 pathway, Nutlin-3 induced maturation also in one AML sample characterized by p53 deletion, as well as in the p53 À/À human myeloblastic HL-60 cell line. At the molecular level, the maturational activity of Nutlin-3 in HL-60 cells was accompanied by the induction of E2F1 transcription factor, and it was significantly counteracted by specific gene knockdown with small interfering RNA for E2F1. Moreover, Nutlin-3, as well as tumor necrosis factor (TNF) A, potentiated the maturational activity of recombinant TNF-related apoptosis-inducing ligand (TRAIL) in HL-60 cells. However, although TNF-A significantly counteracted the proapoptotic activity of TRAIL, Nutlin-3 did not interfere with the proapoptotic activity of TRAIL. Taken together, these data disclose a novel, potentially relevant therapeutic role for Nutlin-3 in the treatment of both p53 wild-type and p53 À/À AML, possibly in association with recombinant TRAIL. Neoplasia (2007) 9, 853-861
Introduction
The human homologue of murine double minute (MDM-2) is an oncogene overexpressed in different types of malignancies, including leukemias (reviewed in Bueso-Ramos et al. [1] ), which plays an important role in cancer development and progression. The best-characterized biologic activity of MDM-2 is to antagonize the transcriptional activity of p53 and to target p53 for ubiquitin-dependent proteolysis [2] . The mdm2 gene is itself transcriptionally activated by p53 in a regulatory feedback loop [3] . It is noteworthy, however, that besides interacting with p53, the mdm2 gene encodes a protein consisting of several domains with different functions: 1) an N-terminal domain that contains binding sites for the transcription factors p53 and E2F1; 2) an acidic domain that interacts with the tumor suppressor p14ARF; 3) a putative Zn finger and a binding site for the retinoblastoma protein Rb; and 4) a RING finger and an E3 ligase domain that are responsible for the ubiquitination of p53 [2, 3] .
Recently, Nutlin-3, a small-molecule inhibitor of MDM-2, has been developed [4] . Nutlin-3 binds to MDM-2, releasing p53 from negative control and leading to effective p53 stabilization and activation in cells with wild-type, but not mutant or deleted, p53 [4, 5] . Of note, recent studies have demonstrated that Nutlin-3, used alone or in combination with chemotherapeutic drugs, effectively increases the degree of apoptosis in acute myeloid leukemia (AML), as well as in other hematologic malignancies characterized by wild-type p53 [6 -9] .
Although the therapeutic effect of most conventional anticancer drugs has been attributed for years to their ability to induce apoptosis, it has been recognized that growth arrest with morphologic features reminiscent of terminal maturation constitutes an alternative drug-induced response program controlled, at least in part, by the p53 pathway [10] . Thus, the experiments illustrated in this study were designed to investigate whether Nutlin-3, used alone or in combination with the death-inducing ligand TNF-related apoptosis-inducing ligand (TRAIL), was able to modulate the maturation of primary blasts obtained by AML patients. Moreover, we have performed a series of experiments in the p53 À/À HL-60 myeloblastic leukemia cell line, which can be induced to undergo monocytic/granulocytic terminal differentiation by a variety of chemical and biologic agents [11, 12] , and based on recent data demonstrating that Nutlin-3 is biologically active in both p53 wild-type and p53-deleted or p53-mutated cells [13] .
Materials and Methods

Patients and Cell Lines
Peripheral blood samples from 10 AML patients were collected in heparin-coated tubes ( Table 1) following their provision of informed consent, in agreement with institutional guidelines. The diagnosis of AML was made by peripheral blood and bone marrow morphology and immune phenotyping. These patients had been without prior therapy. Peripheral blood mononuclear cells from AML patients were isolated by gradient centrifugation with a lymphocyte cell separation medium (Cedarlane Laboratories, Hornby, Ontario), and freshly purified AML blasts were used immediately after purification for different in vitro treatments. The AML patients' cells, as well as the p53 À/À HL-60 and p53 wild-type SKW6.4 cell lines, were cultured in RPMI 1640 (Gibco BRL, Grand Island, NY) supplemented with 10% fetal calf serum (Gibco) and seeded at an optimal cell density of 0.8 Â 10 6 to 1.0 Â 10 6 cells/ml before treatments.
Primary AML blasts or HL-60 cells were treated with predetermined optimal concentrations of Nutlin-3 (10 mM; Sigma Aldrich, St. Louis, MO); recombinant TRAIL (0.1 mg/ ml), prepared as previously described [14] ; or recombinant tumor necrosis factor (TNF) a (10 ng/ml; R&D Systems, Minneapolis, MIN), used either alone or in combination.
Assessment of Apoptosis and Cell Differentiation
At different times (1 -3 days) posttreatment with Nutlin-3, TRAIL, or TNF-a, both cytotoxicity and maturation-inducing activity were assessed. In particular, samples were analyzed by: 1) counting the total number of viable cells by trypan blue dye exclusion; 2) evaluating the degree of apoptosis by Annexin V/propidium iodide (PI) double staining and flow cytometry and/or poly(ADP)ribose polymerase (PARP) cleavage in Western blot analysis; as previously described [15] ; 3) monitoring the cell surface expression of CD14 and CD11b myeloid antigens [16, 17] ; and 4) examining the morphology of the cells by staining with May-Grunwald-Giemsa solution followed by light microscopic examination.
In particular, for flow cytometry analyses, both Annexin V -fluorescein isothiocyanate (FITC)/PI apoptosis kit and CD11b and CD14 phycoerythrin-conjugated or FITC-conjugated antibodies (Abs) were purchased from Immunotech (Marseille, France). Nonspecific fluorescence was assessed by using isotype-matched controls.
Flow cytometry analysis was also used to determine the cell-cycle profile. HL-60 cells were incubated with 50 mM BrdU (Sigma Aldrich) at 37jC for 1 hour. Anti-BrdU was bound to BrdU incorporated into neosynthesized DNA, and the complex was detected by FITC-conjugated secondary Ab. Cells were stained with PI (50 mg/ml) and analyzed by flow cytometry. To avoid nonspecific fluorescence from dead cells, live cells were gated tightly using forward scatter and side scatter. All flow cytometry analyses were performed by using a FACScan flow cytometer and Lysis II software (Becton Dickinson, San Jose, CA).
Western Blot Analysis and Immunoprecipitation
Cells were lysed in a buffer containing 50 mM Tris -HCl pH 8.0, 250 mM NaCl, 0.5% NP-40, 2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 2 mg/ml pepstatin, as described [18] . For Western blot analysis, 50 to 70 mg of protein was resolved on SDS polyacrylamide gels and transferred to nitrocellulose membranes. Blots were incubated with monoclonal Abs anti -MDM-2, anti-p53, anti -DNA repair enzyme PARP (all from Santa Cruz Biotechnology, Santa Cruz, CA), anti -Rb protein (Becton Dickinson), or anti-tubulin (Sigma Aldrich) used for loading control. Membranes were washed and further incubated for 1 hour at room temperature with peroxidase -conjugated secondary Ab (Sigma Aldrich). Detection was then performed using the Renaissance chemiluminescent ECL kit (NEN Dupont, Boston, MA). E2F1 was detected by immunoprecipitation experiments. For this purpose, at least 5 Â 10 6 to 10 Â 10 6 cells/sample were lysed in a buffer containing 50 mM Tris -HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20, 0.5 mM EDTA, and the protease inhibitor cocktail P8340 (Sigma Aldrich). Cell lysates were incubated with a polyclonal E2F1 Ab (Santa Cruz Biotechnology) for 12 hours at 4jC before the addition of 40 ml of A/G Sepharose beads (Santa Cruz Biotechnology) for an additional 3 hours. Immunocomplex was washed thrice with lysis buffer, loaded on 10% PAGE gels, and detected by immunoblotting, as described above. In parallel, for each experiment, equal fractions (5 -10%) of cell lysates from untreated and Nutlin-treated cultures were analyzed by Western blot analysis for tubulin levels, serving as controls of immunoprecipitation inputs.
Protein levels were densitometrically analyzed by the ImageQuant software (Molecular Dynamics, Sunnyvale, CA). Multiple film exposures were used to verify the linearity of the samples analyzed and to avoid saturation of the film.
Transfection Experiments
HL-60 cells (1.2 Â 10 6 cells/0.5 ml) were mixed with 1 mg of enhanced green fluorescence protein (EGFP) plasmid or 2 mg of small interfering RNA (siRNA) cocktails, transferred to a 2.0-mm electroporation cuvette, and nucleofected with the Nucleofector Kit V (Amaxa, Cologne, Germany) using the program T-019 of the Nucleofector device (Amaxa Nucleofector II apparatus). After electroporation, cells were immediately transferred to a complete RPMI supplemented with 10% fetal calf serum and cultured at 37jC until analysis. Transfection efficiency was monitored in each experiment by scoring the percentage of EGFP-positive cells by flow cytometry analysis. siRNA were designed and manufactured by Ambion, Inc. (Austin, TX) according to the method's current guidelines for effective knockdown. The following siRNA were tested: target 1 for E2F1, 5V-CCUGAUGAAUAUCUGUACUtt-3V (sense) and 5V-AGUACAGAUAUUCAUCAGGtg-3V (antisense); target 2 for E2F1, 5V-GGCCCGAUCGAUGUUUUCCtt-3V (sense) and 5V-GGAAAACAUCGAUCGGGCCtt-3V (antisense).
Ambion's Silencer Negative Control siRNA were used to demonstrate that the transfection did not induce nonspecific effects on gene expression. A cocktail of two different negative control siRNA, each composed of a 19-bp scrambled sequence with 3V dT overhangs, was used. The sequences have no significant homology to any known gene sequence from humans and have been previously tested for lack of nonspecific effects on gene expression (Ambion).
Statistical Analysis
The results were evaluated using analysis of variance, with subsequent comparisons by Student's t test and Mann-Whitney rank-sum test. Statistical significance was defined as P < .05.
Results
Nutlin-3 Induces Variable Levels of Cytotoxicity in Primary AML Blasts
To investigate the effect of Nutlin-3 on cell viability, AML samples freshly isolated from patients free of therapy were incubated in vitro with predetermined optimal concentrations of Nutlin-3 (10 mM) and were assayed for viability by trypan blue dye exclusion at 72 hours of treatment (Table 1 ). During this time frame, the number of viable cells in untreated cultures remained relatively constant, never dropping below 70% compared to the cell number seeded at time 0 (1 Â 10 6 cells/ml). On Nutlin-3 treatment, a variable decrease in cell viability (61 ± 18.5; mean ± SD of the percentage of cell viability compared with untreated controls; Table 1) was observed, with all patient samples being susceptible to Nutlin-3 cytotoxicity, with the exception of patient 5. The decrease in cell viability induced by Nutlin-3 was paralleled by a concomitant increase in the percentage of apoptosis, evaluated in terms of Annexin V -positive cells (data not shown) and/or PARP cleavage ( Figure 1 ) with respect to control cultures.
As expected based on previous studies [4] [5] [6] [7] [8] [9] , on Western blot analysis, Nutlin-3, efficiently, although variably, upregulated p53 protein levels, as well as MDM-2, in all AML samples, with the exception of patient 5 (Figure 1 ). The lack of induction of p53 in response to Nutlin-3 observed in patient 5 (Figure 1 ) has been previously shown to be a characteristic feature of tumor samples wherein p53 was deleted [4 -9] .
Nutlin-3 Promotes Myeloid Maturation in Primary AML Blasts Independently of Its Proapoptotic Activity
Because an alternative therapeutic strategy to the induction of apoptosis is to promote terminal growth arrest and maturation of AML blasts, in the next experiments, we have investigated whether Nutlin-3 was able to modulate the phenotypic profile and morphology of AML cells that survived Nutlin-3 cytotoxicity. Independently of the basal expression of CD11b and CD14 antigens that was variable from sample to sample (data not shown), Nutlin-3 treatment showed a significant (P < .05) induction of both surface CD11b and CD14 antigens at 72 hours (Figure 2A ). It should be noticed that CD14 represents an excellent marker of monocytic maturation because it is undetectable on the surface of monocyte precursors and increases dramatically during their differentiation into monocytes [16] . Surface CD11b, particularly the b 2 integrin CR3, is another classic marker of myeloid differentiation that is involved in cell adhesion and also functions as a complement receptor [17] .
Flow cytometry results were confirmed by morphologic analyses, which showed an increment of cells with monocytic features following Nutlin-3 treatment ( Figure 2B ). It is particularly noteworthy that the ability of Nutlin-3 to promote myeloid maturation occurred also in the p53-deleted patient sample (patient 5; Figure 2B ), indicating that the promaturative effect of Nutlin-3 was totally unrelated to its ability to induce apoptotic cell death.
Nutlin-3 Promotes Maturation of the p53 À/À Myeloblastic HL-60 Cell Line in an E2F1-Dependent Manner
The data obtained on primary AML blast samples suggested that Nutlin-3 might affect myeloid maturation not only in p53 wild-type cells but also in p53 À/À cells. To further ascertain whether this biologic activity of Nutlin-3 occurred independently of p53, the next experiments were performed on the p53 À/À AML HL-60 cell line ( Figure 3A) . Nutlin-3 alone did not induce a significant increase in apoptosis in HL-60 Figure 3B ), in keeping with a central role of the p53 pathway in mediating the proapoptotic activity of Nutlin-3 [4 -9] . In spite of the lack of induction of cytotoxicity, treatment with Nutlin-3 induced a progressive increase in the surface expression of both CD11b and CD14 in p53 À/À HL-60 cells ( Figure 3C ). Moreover, the ability of Nutlin-3 to upregulate the surface levels of CD11b and CD14 in HL-60 was more evident than in primary AML blasts, suggesting that this cell line is a good model for the study of the maturational effects of Nutlin-3.
Because previous studies have shown that differentiation of HL-60 cells was accompanied by exit from the cell cycle [11, 12, 16, 17, 19] , the next experiments were performed to investigate whether Nutlin-3 induced changes in the cellcycle distribution of HL-60 cells. As shown in Figure 4A , Nutlin-3 induced a significant (P < .05) accumulation of HL-60 in the G 2 /M phase of the cell cycle. The ability of Nutlin-3 to promote the accumulation of HL-60 cells in the G 2 /M phase was markedly different from the biologic activity of other compounds, such as the natural compound saucernetin-7, which promoted cell-cycle arrest in G 0 /G 1 coupled to the monocytic maturation of HL-60 cells [19] . Because MDM-2 has been shown to modulate the levels of Rb protein [20, 21] , the levels of this transcription factor were analyzed by Western blot analysis ( Figure 4B ). At variance with other maturational compounds, which induced a progressive increase in the hypophosphorylated form of Rb protein [19] , Nutlin-3 decreased the total levels of Rb protein in HL-60 cells ( Figure 4B ).
Besides interacting with p53 and Rb protein, MDM-2 also interacts with other transcription factors, which play an important role in the regulation of cell-cycle progression and maturation [2, 3] . In particular, it has been recently shown that Nutlin-3 induced the expression of E2F1 in cell lines derived from solid tumors [13] . Therefore, we next investigated the effect of Nutlin-3 on E2F1 expression in HL-60 cells. Because the amount of E2F1 in HL-60 and AML patient cell lysates was too low to be detected by Western blot analysis on whole-cell lysates (data not shown), immunoprecipitation assay was performed. As shown in Figure 4C , treatment with Nutlin-3 induced the accumulation of E2F1 protein in the p53 À/À HL-60 leukemic cell model. Of note, a similar effect was observed in selected p53 wild-type AML samples, for which a sufficient number of cells were available for the performance of E2F1 immmunoprecipitation assay ( Figure 4C) .
In an attempt to further elucidate the role of E2F1 in AML maturation induced by Nutlin-3, we have used a gene knockdown approach. The transfection procedure adopted in these experiments allowed to efficiently transfect 40 ± 5% of HL-60 cells ( Figure 5A ). HL-60 cells were transfected with a cocktail of two siRNA specific for E2F1 or with control scrambled siRNA; 48 hours after transfection, cultures were either left untreated or exposed to Nutlin-3. The efficiency and specificity of gene knockdown were documented by the ability of E2F1 siRNA, but not scrambled siRNA, to re-duce the induction of E2F1 protein by Nutlin-3 treatment ( Figure 5B ). In parallel, we could demonstrate that transfection with E2F1 siRNA, but not with scrambled siRNA, significantly (P < .05) counteracted the promaturative activity of Nutlin-3 evaluated in terms of CD14 and CD11b surface expression ( Figure 5B ).
Nutlin-3 Potentiates the Maturational Activity of Recombinant TRAIL
Having previously demonstrated that the TNF family member TRAIL promotes both apoptotic cell death and maturation of the HL-60 myeloid cell line [22] , the next experiments were performed to evaluate the effects of the combined treatment Nutlin-3 + TRAIL on both apoptosis and myeloid maturation of HL-60 cells. As shown in Figure 6 , A and B, Nutlin-3 significantly (P < .05) enhanced the ability of 
Nutlin-3 Promotes Maturation of AML Blasts
Secchiero et al.
both TRAIL and TNF-a, the prototype member of the TNF superfamily, to promote the maturation of HL-60 cells. Besides the induction of maturation, it is also noteworthy that TRAIL markedly (P < .05) induced the apoptosis of HL-60 cells, whereas neither Nutlin-3 nor TNF-a alone significantly modulated the degree of apoptosis over the background level ( Figure 6C ). However, although Nutlin-3 did not interfere with the cytotoxic activity of TRAIL, TNF-a significantly (P < .05) counteracted the ability of TRAIL to induce apoptosis ( Figure 6C ).
Discussion
We have here shown for the first time that the small-molecule inhibitor of MDM-2 Nutlin-3 promotes the maturation of both p53 wild-type and p53 À/À leukemic cells along the myelocytic/ monocytic lineage. It is particularly remarkable that such maturational effect was dissociated from the ability of Nutlin-3 to induce apoptosis in AML blasts. It should also be emphasized that although previous studies of our and other groups have demonstrated the inhibitory effects of Nutlin-3 on the survival of different types of hematologic malignancies, including AML [5 -9] , this study represents a demonstration of the positive regulative effect of Nutlin-3 on primary AML blasts and HL-60 leukemic cells. Thus, the ability of Nutlin-3 to promote the myeloid maturation of both primary AML blasts and HL-60 cells envisions an additional role of Nutlin-3 as an antineoplastic agent, at least for certain types of AML. In fact, induction of mortality by terminal differentiation represents an alternative approach to the cytodestruction of cancer cells by conventional antineoplastic agents and has important biologic implications. Indeed, it indicates that the malignant state is not an irreversible one and suggests that certain leukemias may eventually be treated with agents that initiate terminal maturation, presumably with less morbidity than that produced by cytodestructive agents [23] . In this respect, retinoid acids are well-known inducers of the granulocytic differentiation of primary acute promyelocytic leukemia blasts and leukemic cell lines, apparently acting through transcriptional regulation of critical genes [24] . In fact, both retinoids and vitamin D 3 interact with nuclear receptorsmembers of the steroid/thyroid hormone receptor superfamily of transcription factors [25] . These are ligand-inducible trans regulators that modulate the transcription of genes, which play a central role in the control of cell growth and differentiation by interacting with retinoic acid or vitamin D 3 cis-acting DNA-responsive elements [24, 25] . However, although some retinoids are currently used in the treatment of acute promyelocytic leukemia (the M3 type of AML), agonists such as vitamin D 3 (which are able to induce monocytic differentiation in other subtypes of AML and, in particular, in M4 and M5 types) did not demonstrate efficacy in clinical trials performed in AML patients, mainly due to secondary hypercalcemia, thus limiting the dose of vitamin D 3 that could be administered [26] .
Similarly to previous studies [11, 12, 19] , we have also shown that the ability of Nutlin-3 to promote HL-60 maturation was coupled to significant modifications in cell-cycle regulation. However, although a cell-cycle block at the G 0 /G 1 checkpoint has been previously reported [19] , our current study demonstrates that Nutlin-3 induced cell-cycle accumulation in G 2 /M. Thus, Nutlin-3 appears to act differently on the cell cycle of leukemic HL-60 cells, as also underlined by the fact that although accumulation of HL-60 cells in G 0 /G 1 was accompanied by accumulation of the hypophosphorylated form of Rb protein [19] , Nutlin-3 induced the downregulation of Rb protein in HL-60 cells. In this respect, our findings are in line with a recent study in which a similar downregulation of Rb protein was observed by treatment with Nutlin-3 cell lines derived from solid tumors [13] .
It has been shown that the p53 tumor-suppressor gene is involved in the differentiation of myeloid lineage [27 -29] and that overexpression of p53 in the HL-60 cell line is able to induce differentiation along the granulocytic or monocytic pathway [30, 31] . However, these previous data cannot entirely account for our present findings. In fact, we found that Nutlin-3 induces the maturation of both p53 wild-type and p53 À/À primary AML blasts, as well as of the p53 À/À HL-60 cell line. In an effort to elucidate the molecular mechanism underlining the ability of Nutlin-3 to promote maturation even in p53 À/À AML cells, we could demonstrate that Nutlin-3 induced E2F1 transcription factor, a phenomenon anticipating the differentiation of HL-60 cells. The ability of Nutlin-3 to upregulate E2F1 was in line with the findings of Ambrosini et al. [13] , who found that in the p53 À/À HCT116 colon carcinoma cell line, Nutlin-3 disrupted the binding of E2F1 to MDM-2 and induced the transcriptional activation of free E2F1. However, Nutlin-3 induced the degradation of E2F1 in p53 wild-type cells. The interpretation of these findings was that the loss of E2F1 expression following Nutlin-3 therapy in p53 wild-type cells appears to be mediated by increased ubiquitination and subsequent proteasomal degradation, whereas in cells with nonfunctional p53 (p53 À/À HCT cells), Nutlin-3 decreases the ubiquitination of E2F1, avoiding degradation by the proteasome and making it available for the transcriptional activation of E2F1-related proapoptotic molecules. Taken together, the findings of Ambrosini et al. [13] and our present data suggest that E2F1 might substitute for p53 in mediating myeloid maturation in p53 À/À AML cells. Moreover, although Ambrosini et al. [13] have described the need for simultaneous treatment with cisplatin to observe an increase in E2F1 in the p53 À/À HCT116 cell line, we have shown that treatment with Nutlin-3 alone was sufficient to induce E2F1 in the HL-60 cell model.
Although the E2F1 transcription factor has been shown to promote either cell proliferation or apoptotic cell death, in relationship with the cell context [30, 31] , studies performed on E2F1 À/À knockout mice have unequivocally demonstrated the development of a broad spectrum of tumors, suggesting that E2F1 in vivo mainly functions as a tumor suppressor. Furthermore, although the overexpression of E2F1 in the p53 À/À M1 myeloblastic leukemia cell lines counteracts IL-6 -driven terminal differentiation and maintains leukemogenicity [32] , knocked-down mice for E2F transcription factors significantly impaired normal hematopoiesis, with defects at the bone marrow level of both erythroid and myeloid lineages and with a reduced release of mature red blood cells and macrophages [33] .
In conclusion, our present study suggests that a therapeutic regimen including Nutlin-3 (possibly in association with recombinant TRAIL) would optimize anticancer activity against leukemic cells by a two-fold mechanism: cytotoxicity in p53 wild-type cells and induction of differentiation along the monocytic lineage in both p53 wild-type and p53-deleted cells.
